Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect the efficacy and safety information in subjects who
have been retreated with varenicline (Champix®) within 52 weeks of initial treatment for
their appropriate use in daily practice and are participants for varenicline Drug Use
Investigation protocol A3051109 ((NCT# NCT00772941).